Dataset Information


Evaluation of AGP Fucosylation as a Marker for Hepatocellular Carcinoma of Three Different Etiologies.

ABSTRACT: A mass spectrometric analysis platform has been developed to determine whether glycosylation patterns of alpha-1 acid glycoprotein (AGP) could be used as a marker for early detection of hepatocellular carcinoma (HCC) in different etiologies, i.e. non-alcoholic steatohepatitis (NASH), alcoholic liver disease (ALC), and hepatitis C virus (HCV). MALDI-MS profiling of N-glycans of AGP purified from 20 μL of patient serum in HCC (n = 72) and liver cirrhosis (n = 58) showed that a unique trifucosylated tetra-antennary glycan (m/z 3490.76) was predominantly identified in HCCs but was absent in healthy subjects and the majority of cirrhosis patients. Receiver operation characteristic (ROC) curve analysis showed that the trifucosylated N-glycan of AGP (triFc_AGP) could differentiate HCC from cirrhosis with an area under the curve (AUC) of 0.707, 0.726 and 0.751 for NASH, ALC and HCV, respectively. When combining triFc_AGP with INR and AFP, the panel had the greatest benefit in detection of NASH-related HCCs, with a significantly improved AUC of 0.882 for all NASH HCCs and 0.818 for early NASH HCCs compared to AFP alone (0.761 and 0.641, respectively). Moreover, triFc_AGP could serve as a potential marker for monitoring AFP-negative HCC patients.


PROVIDER: S-EPMC6689003 | BioStudies | 2019-01-01

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7429342 | BioStudies
1000-01-01 | S-EPMC4059532 | BioStudies
2015-01-01 | S-EPMC4636958 | BioStudies
1000-01-01 | S-EPMC6315895 | BioStudies
2018-01-01 | S-EPMC5983165 | BioStudies
2009-01-01 | S-EPMC2714725 | BioStudies
2020-01-01 | S-EPMC7646160 | BioStudies
2008-02-01 | GSE10356 | GEO
2014-01-01 | S-EPMC4462359 | BioStudies
2017-01-01 | S-EPMC5395802 | BioStudies